Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) has demonstrated significantly better results over conventional imaging for the direction of metastasis-directed therapy (MDT) for oligometastatic renal cell carcinoma (RCC). A recent proof-of-concept study has further evaluated the efficacy of PSMA-guided MDT for oligometastatic RCC. ...
Localized Renal Cell Carcinoma
Advertisement
Latest News
Dr. Kaouk explains how a multidisciplinary team should be integrated into the management of RCC.
Dr. Karam explains the main points of emphasis when it comes to small renal masses and surveillance versus surgery.
Radical nephrectomy was associated with a greater decline in postoperative eGFR compared with partial nephrectomy.
The standard of care for intermediate to high-risk RCC consists of partial or radical nephrectomy and surveillance.
Dr. Albiges breaks down a biomarker analysis of circulating kidney injury molecule-1 in the IMmotion010 trial.
Researchers analyzed the connection between the outcomes and specific predictors of interest.
Advertisement
Knowledge Hub Spotlight
Curated clinical content based on conditions, therapies, and technologies
Conference Coverage
Noah Hahn, MD, gives an overview of durvalumab with intravesical gemcitabine and docetaxel for BCG-unresponsive NMIBC.
Dr. Daniel Joyce gives an overview of his study that examined the use of necrosis as a prognostic indicator for mRCC.
Drs. Karine Tawagi and Samantha Armstrong expand on the prostate cancer discussions of note, including TALAPRO-2.
Drs. Tawagi and Armstrong provide detail and discussion on the bladder cancer research from the 2025 ASCO GU meeting.
Drs. Tawagi and Armstrong recap the hottest topics in kidney cancer research from the 2025 ASCO GU Cancers Symposium.
Dr. Sonpavde provides an update on the latest analysis from the phase 3 global study of EV in combination with pembro.
Advertisement
Advertisement
Latest News
Enzalutamide with [177Lu]Lu-PSMA-617 improved OS and HRQOL, along with PSA PFS.
Dr. Tan discusses the TALAPRO-2 study, PARP inhibitor synergy, HRR testing, and evolving treatment strategies in mCRPC.
COSMIC-021 began in 2017 to analyze the effects of cabozantinib alone or with atezolizumab for advanced solid tumors.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.